Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors.
about
Tumor resistance to vascular disrupting agents: mechanisms, imaging, and solutionsA combretastatin-mediated decrease in neutrophil concentration in peripheral blood and the impact on the anti-tumor activity of this drug in two different murine tumor modelsSegmentation of dynamic contrast enhanced magnetic resonance imaging data.Early effects of combretastatin-A4 disodium phosphate on tumor perfusion and interstitial fluid pressureA Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer.Anti-angiogenesis therapies: their potential in cancer managementThe unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents.Treatment with the vascular disrupting agent combretastatin is associated with impaired AQP2 trafficking and increased urine output.The biology of the combretastatins as tumour vascular targeting agents.Treatment with a vascular disrupting agent does not increase recruitment of indium labelled human endothelial outgrowth cells in an experimental tumour model.A perspective on vascular disrupting agents that interact with tubulin: preclinical tumor imaging and biological assessmentAn in vivo role for Rho kinase activation in the tumour vascular disrupting activity of combretastatin A-4 3-O-phosphate.Anaplastic thyroid cancer: a review of epidemiology, pathogenesis, and treatment.Evaluation of tumor ischemia in response to an indole-based vascular disrupting agent using BLI and (19)F MRI.Combretastatin A4 phosphate: background and current clinical status.Vascular effects of plinabulin (NPI-2358) and the influence on tumour response when given alone or combined with radiation.Tumour targeting by microtubule-depolymerizing vascular disrupting agents.Vascular targeted therapies in oncology.Tumour vascular disrupting agents: combating treatment resistance.Myocardial stunning following combined modality combretastatin-based chemotherapy: two case reports and review of the literature.Combretastatin A4-phosphate and its potential in veterinary oncology: a review.Prevention of cancer recurrence in tumor margins by stopping microcirculation in the tumor and tumor-host interfaceAssessment of the novel tubulin-binding agent EHT 6706 in combination with ionizing radiation or chemotherapy.Non-invasive imaging of combretastatin activity in two tumor models: Association with invasive estimates.Dissemination via the lymphatic or angiogenic route impacts the pathology, microenvironment and hypoxia-related drug response of lung metastases.Radiotherapy in combination with vascular-targeted therapies.Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy.Schedule dependence of combretastatin A4 phosphate in transplanted and spontaneous tumour models.Tumor blood flow interruption after radiotherapy strongly inhibits tumor regrowth.The new vascular disrupting agent combretastatin-A1-disodium-phosphate (OXi4503) enhances tumour response to mild hyperthermia and thermoradiosensitization.Induction of hypoxia by vascular disrupting agents and the significance for their combination with radiation therapy.Enhancing the radiation response of tumors but not early or late responding normal tissues using a vascular disrupting agent.The effects of the vascular disrupting agents combretastatin A-4 disodium phosphate, 5,6-dimethylxanthenone-4-acetic acid and ZD6126 in a murine tumour: a comparative assessment using MRI and MRS.Trapping effect on a small molecular drug with vascular-disrupting agent CA4P in rodent H22 hepatic tumor model: in vivo magnetic resonance imaging and postmortem inductively coupled plasma atomic emission spectroscopy.
P2860
Q26774355-71C0A54A-4DC8-4140-82F1-A56F46FA8524Q28543671-783E5A73-0CB0-4CAA-A9D3-4DB93EC48B69Q31165580-721FE5C6-42CF-4247-BDCB-899CDB2B6BB2Q33278296-4D6AEFE4-14C0-4614-AA9C-BADAA04B1B68Q33389126-B1E06A26-0DB3-4700-A7AC-6F5C1F43EC8CQ33956056-19ADF85E-76D8-40DF-9794-6CE9DA50A312Q34122191-4175B056-C561-4FBC-BBCC-D4178B14A02DQ34279269-826D0D49-3BD0-4C86-95B9-A72405FD9848Q34680614-B2C7FD47-DB88-4C0B-92E7-0CAEFE9378D9Q34694874-B5023B61-6221-4EAC-8F8E-FFCA7371918BQ34765364-B446A4F6-B073-43CD-B596-0DB15C630C7EQ34954063-1367CB2C-B87C-431B-8BDB-BB653651713FQ35104726-65CFC266-1E70-4794-9FB0-93F82C72AA14Q35402062-B0C3794B-577F-46FF-99A1-06C1A39E5942Q35871932-D3CCC997-D98C-4A26-BD76-8AE155D15C10Q36433061-CF39ADED-BA7C-4828-BE09-EA0A5C760C75Q37008845-562A99C9-DD3D-40B0-A94A-C6B36B945440Q37254370-AB67B7F8-B2CF-4F0B-85A8-CAFA67D81847Q37280244-D455FE9C-5F1E-4E8E-A681-7CCC4623428CQ37656010-B28A1E4F-FBA0-4E06-9445-9104BF13570BQ38490875-169BC6DC-C1AA-4147-9233-2C7F8C7AE904Q38979348-CE2945C9-9B71-4B9F-AAF3-116C114029BDQ39412065-AA2E8A92-ABDC-49F3-8C6E-2725E5A7E471Q39657204-E3317505-73D4-42A8-A34C-F4E68E244BE7Q40795709-83AA3204-869C-4963-B97A-7074FC7ABEC6Q42203737-197D8615-AFBD-4E83-8275-B1ECA67D4E8AQ43956053-1B1FBB74-7318-4158-8CD9-4AE2923D9870Q44157516-E16E875D-7483-43BD-B53F-92CA60F133D8Q46614854-C9DFA01E-A783-4564-B058-46ACE2BA3E5DQ46882346-3F76CD7D-5F20-46DE-A75D-FD01D98C4164Q51210513-69DD0E9C-66AF-484F-8E60-8EDD4E0DA9E1Q51801476-2C8FC6F8-F1F8-46AE-A3D0-F95F53D0304DQ51808119-74ECB24C-FE52-4AD5-A694-8D3F9DDD9F4AQ52656539-1349031D-9E67-4BD1-8966-4089C43332AA
P2860
Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors.
description
2001 nî lūn-bûn
@nan
2001 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors.
@ast
Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors.
@en
type
label
Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors.
@ast
Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors.
@en
prefLabel
Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors.
@ast
Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors.
@en
P2093
P1476
Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors.
@en
P2093
Horsman MR
Overgaard J
Siemann DW
P304
P356
10.1016/S0167-8140(01)00384-X
P577
2001-08-01T00:00:00Z